fMRI in 386 MDD Patients Identifies Shared Visual-Thalamic Connectivity Rise and Subset-Specific SSRI Effects After 1-2 Weeks

The Nature Mental Health analysis combined two independent cohorts totaling 386 adults aged 18-65 with major depressive disorder. Participants underwent baseline and week-1 or week-2 resting-state fMRI while receiving placebo (n=125), sertraline (n=123), or escitalopram (n=138). Machine-learning contrastive models isolated a connectivity increase within visual-precuneus-thalamus circuitry that occurred across all arms irrespective of clinical outcome. In the placebo arm, symptom improvement correlated with strengthened striatal and dorsal-attention network connectivity, consistent with prior reward-learning accounts of placebo analgesia.

Drug-specific signatures centered on amygdala, midcingulate, orbitofrontal, and cerebellar nodes but were detectable in only a minority of SSRI-treated patients; those lacking the signature could be reclassified by a placebo-response model. This dissociation suggests that early imaging may eventually triage patients toward pharmacotherapy versus non-specific interventions. The design improves on earlier single-drug or cross-sectional fMRI studies by using two active SSRIs, a placebo control, and predictive modeling within the same sample.

Next steps require prospective validation: whether early connectivity trajectories prospectively predict 8-week remission rates above chance in an independent cohort, and whether they moderate outcomes when treatment is assigned by imaging versus usual care. Such data would clarify whether the observed patterns are mechanistic mediators or merely correlated epiphenomena.